ArticleThe Lancet regional health. Western Pacific2023
Molecular and clinical epidemiology of carbapenem resistant
Article in The Lancet regional health. Western Pacific, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 25 citations in OpenAlex.
- The population structure ofApplied and environmental microbiology · 2026Article
- A genome-wide association study to identify the genetic loci underlying carbapenem resistance in Acinetobacter baumannii.BMC genomics · 2026Article
- Antimicrobial susceptibility trends of WHO critical Gram-negative pathogens in Fijian Hospitals, 2016-2021.JAC-antimicrobial resistance · 2026Article
- Genomic and phenotypic characterization of carbapenem-resistant Acinetobacter baumannii isolates from patients and trolleys and their potential connections in an intensive care unit.BMC microbiology · 2026Observational
- Novel Insights into Carbapenem Resistance: Mechanisms, Diagnostics, and Future Directions.Antibiotics (Basel, Switzerland) · 2026Review
- Impact of intensive care unit relocation on the transmission dynamics of carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- Clonal lineage and biofilm growth shape cefiderocol activity inFrontiers in cellular and infection microbiology · 2026Article
- Virulence factors are preserved within carbapenem-resistantVirulence · 2025Article
- Drug-resistant gram-negative bacterial infections in children in the Oceania region: review of the epidemiology, antimicrobial availability, treatment, clinical trial and pharmacokinetic data, and key evidence gaps.The Lancet regional health. Western Pacific · 2025Review
- Six-year retrospective analysis of the epidemiology and risk factors of multidrug-resistant bloodstream infections in oncology patients in Jiangxi, China.Microbiology spectrum · 2025Article
- The evolution of the multidrug-resistant and globally distributed ST2 Acinetobacter baumannii in China.BMC microbiology · 2025Article
- Susceptibility toward cefiderocol and sulbactam-durlobactam in extensively drug-resistantMicrobiology spectrum · 2025Article
- Genomic diversity of clinically relevant bacterial pathogens from an acute care hospital in Suva, Fiji.JAC-antimicrobial resistance · 2025Article
- Genomic landscape of nosocomial Acinetobacter baumannii: A comprehensive analysis of the resistome, virulome, and mobilome.Scientific reports · 2025Article
- Establishing carbapenem resistant organism surveillance, prevention, and control in a middle-income country: implementation of a hospital-based program in Fiji.Antimicrobial resistance and infection control · 2025Article
- Whole-genome sequencing ofMicrobial genomics · 2025Article
- Phylogenomic analysis of OXA-23-positive and genetic context of rare NDM-1-producing carbapenem-resistantFrontiers in microbiology · 2025Article
- The intricacies ofFrontiers in microbiology · 2025Review
- Antimicrobial resistance and virulence factors analysis of a multidrug-resistant Acinetobacter baumannii isolated from chickens using whole-genome sequencing.BMC microbiology · 2024Article
- Successful management of a multi-species outbreak of carbapenem-resistant organisms in Fiji: a prospective genomics-enhanced investigation and response.The Lancet regional health. Western Pacific · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 7 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carbapenem resistant Methods: In this multicountry cohort study, we analysed clinical isolates of CR Findings: Of CR Interpretation: We identified unrecognised outbreaks of CR Funding: This project was funded by an Otago Global Health Institute seed grant and Maurice Wilkins Centre of Research Excellence (CoREs) grant (SC0000169653, RO0000002300).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.